Process for the synthesis of ELAGOLIX sodium salt and intermediates of said process
By optimizing the six synthesis steps of Elagolix sodium salt, the problems of high equipment investment, long execution time and complex chromatographic fractions in the existing technology are solved, and the Elagolix sodium salt with high efficiency on industrial scale is realized, and the process is simplified Process and improve productivity and product purity.
Patent Information
- Application Number
- CN202080062002.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-24
- Filing Date
- 2020-07-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-07-27
AI Technical Summary
The existing Elagolix sodium salt synthesis process is not suitable for industrial-scale production, and there are problems such as high investment in equipment, long execution time, multiple organic solvent use and complex chromatographic fraction control.
The process of six synthesis steps, including reaction of N-6 with D-BOC-phenylglycyl alcohol to form intermediate N-5, followed by hydrochloric acid treatment to form intermediate N-4, followed by alkali treatment and ethyl 4-bromobutyric acid Ester reaction forms intermediate N-3, protonic acid treatment forms intermediate N-2, and then reacts with 2-fluoro-3-methoxyphenylboric acid to form intermediate N-1, and finally hydrolyzes with sodium hydroxide to form sodium Elagolix Salt. The process is optimized in temperature and time, reducing the generation of by-products.
The Elagolix sodium salt with high efficiency in drug quality on industrial scale has been achieved, reducing the use of equipment and solvents, simplifying the chromatographic fractionation process, and improving production efficiency and product purity.
Smart Images

Figure CN114641468B_ABST
Abstract
Description
Field of the Invention
[0001] The present invention relates to the field of processes for the synthesis of active ingredients for pharmaceutical use, and in particular to a process for the industrial-scale preparation of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)methyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butyric acid. The present invention also relates to some intermediates of the process.
[0002] The compound, also known as Elagolix sodium salt, is an active ingredient that can be used to treat pain associated with endometriosis in women. It is also in development for the treatment of uterine fibroids and heavy menstrual bleeding in women.
[0003] The structural formula of Elagolix and its sodium salt is reported as follows:
[0004]
[0005] background
[0006] The sodium salt of Elagolix (hereinafter also referred to as Elagolix sodium salt or "Elagolix sodium") is described and claimed in patent EP 1646389 Bl dated 2006 in the name of Neurocrine Biosciences Inc.
[0007] The patent reports a detailed experimental description of the preparation of the target compound. Example 1 of the patent, on pages 14-16, reports a process for synthesizing the sodium salt of Elagolix starting from 2-fluoro-6-(trifluoromethyl)benzonitrile; the process layout of the patent is reported as Scheme 1 below:
[0008]
[0009] The synthetic steps 1d→1e
[0062] , 1e→1f
[0063] , 1f→1g
[0066] and 1g→Elagolix sodium salt
[0067] all contemplate chromatographic purification. In particular, steps 1d→1e
[0062] , 1e→1f
[0063] , 1f→1g
[0066] require preliminary chromatography on silica gel, while the final step from 1g→Elagolix sodium salt
[0067] requires chromatography on an ion exchange resin.
[0010] These purification techniques are not a priori unsuitable for industrial-scale production, but require investments in equipment, execution time, use of organic solvents and analytical commitment for controlling chromatographic fractions that practically exclude their application.
[0011] There is still a need to obtain a new synthesis process of Elagolix sodium salt which overcomes the disadvantages of the above processes.
[0012] The object of the present invention is to provide a synthetic route for the preparation of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butyric acid (Elagolix sodium salt), which is industrially applicable and enables a product of pharmaceutical quality to be obtained, overcoming the key problems associated with the described processes of the prior art. SUMMARY OF THE INVENTION
[0014] This object is achieved by the present invention which, in its first aspect, relates to a process for synthesizing the sodium salt of Elagolix comprising the following steps:
[0015] a) reacting the compound N-6,5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione with D-BOC-phenylglycinol to obtain the intermediate 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-pyrimidine-2,4(1H,3H)-dione (intermediate N-5):
[0016]
[0017] b) treating intermediate N-5 with hydrochloric acid in a solvent selected from ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone (MIBK), ethyl acetate, isopropyl acetate or a mixture thereof to obtain intermediate 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[2(R)-amino-2-phenylethyl]-pyrimidine-2,4(1H,3H)-dione hydrochloride (intermediate N-4):
[0018]
[0019] c) Intermediate N-4 is treated with a base and reacted with ethyl 4-bromobutyrate at a temperature between 30°C and 55°C for a period between 18 hours and 48 hours to obtain intermediate N-3,3-[2(R)-{ethoxycarbonylpropylamino}-2-phenylethyl]-5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione:
[0020]
[0021] d) Hydrogenation of intermediate N-3 with proton acid to obtain intermediate N-2:
[0022]
[0023] e) reacting the intermediate N-2 with 2-fluoro-3-methoxyphenylboronic acid to obtain the intermediate N-1,3-[2(R)-{ethoxycarbonylpropylamino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione:
[0024]
[0025] f) Forming the sodium salt of Elagolix by reacting the intermediate N-1 with sodium hydroxide:
[0026]
[0027] In an alternative embodiment of the process of the present invention, in case step c) and step d) are carried out in the same solvent, these two steps can be carried out as a single step to obtain intermediate N-2 directly from intermediate N-4.
[0028] In a second aspect of the invention, the invention relates to intermediates N-4, N-3 and N-2 of the process described above. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Shown is the HPLC chromatogram of the sodium salt of Elagolix obtainable by the process of the present invention.
[0031] Figure 2 Shown is an HPLC chromatogram obtained using a chiral column of Elagolix sodium salt obtainable by the process of the present invention.
[0032] Figure 3 Two conformational isomers of Elagolix obtained in the mixture of the process of the present invention are shown.
[0033] Figure 4 The DRX diffraction spectrum of intermediate N-2 which can be obtained following the experimental procedure of Example 11 is shown.
[0034] Figure 5 The DSC thermogram of intermediate N-2 which can be obtained following the experimental procedure of Example 11 is shown.
[0035] Figure 6 The FT-IR spectrum of intermediate N-2 which can be obtained following the experimental procedure of Example 11 is shown. DETAILED DESCRIPTION OF THE INVENTION
[0037] In a first aspect of the invention, the present invention relates to a process for the synthesis of the sodium salt of Elagolix, which process requires six synthetic steps.
[0038] The first step a) uses compound N-6 as a reactant:
[0039]
[0040] The starting reactant compound N-6 of this step can be obtained as described in patent EP 1646389 B1.
[0041] The reaction from compound N-6 to intermediate N-5 can also be carried out according to the instructions reported in the cited patents.
[0042] However, unlike what is described in the patent, intermediate N-5 is not purified by chromatography, but by treating the crude product with an organic ester such as ethyl acetate (AcOEt), butyl acetate (BuOAc) or isopropyl acetate (iPrOAc). The use of isopropyl acetate (iPrOAc) is preferred. Such treatment can be carried out at a temperature between 0°C and 25°C, preferably between 5°C and 15°C.
[0043] Step b) involves forming the hydrochloride salt of intermediate N-5 (which constitutes intermediate N-4):
[0044]
[0045] This step can be carried out by preparing a solution of the intermediate N-5 in an organic solvent (compatible with the presence of hydrochloric acid) and then adding hydrochloric acid thereto. The hydrochloric acid can be introduced directly into the solution of the intermediate N-5 as a gas (e.g., by bubbling), or, preferably, the hydrochloric acid can be added as an aqueous solution or as a previously prepared solution in the same organic solvent in which the intermediate N-5 was previously dissolved.
[0046] Solvents that can be used are ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone (MIBK), ethyl acetate, isopropyl acetate, pure or mixed together. The preferred solvent is ethanol.
[0047] The reaction temperature is between 5°C and 35°C, preferably between 20°C and 30°C.
[0048] Step c) of the process of the invention comprises converting intermediate N-4 into intermediate N-3:
[0049]
[0050] This step can be carried out according to the sequence of two operations, wherein the first operation c.1 consists in suspending the intermediate hydrochloride N-4 in an organic ester such as ethyl acetate (AcOEt), butyl acetate (BuOAc) or isopropyl acetate (iPrOAc) and treating the intermediate hydrochloride N-4 with an inorganic base; the second operation c.2 consists in reacting the amine function released in operation c.1 with the compound 4-bromo-butyric acid ethyl ester. Preferably, the organic ester used in operation c.1 is isopropyl acetate (iPrOAc).
[0051] The reaction temperature of operation c.2 is between 30° C. and 55° C., preferably between 30° C. and 50° C., and requires a time between 18 hours and 48 hours.
[0052] Higher temperatures lead to an increase in by-products which are detrimental to the formation of the reaction product (in this respect, see Comparative Example 7 carried out at T=80° C.).
[0053] Step d) consists in forming a salt of the intermediate N-3 (which constitutes the intermediate N-2) by reaction with a protic acid:
[0054]
[0055] This step is performed by preparing a solution of intermediate N-3 in an organic solvent (compatible with the presence of the protic acid) and then adding the protic acid thereto.
[0056] Although the protonic acid is represented by the general formula AH, it is not limited to a monoprotic acid that can only produce one proton. The acid can be selected from hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, p-toluenesulfonic acid or trifluoroacetic acid. Preferably, hydrochloric acid or phosphoric acid H3PO4 is used.
[0057] The acid can be introduced neat into the solution of intermediate N-3 (for example in gaseous form in the case of hydrochloric acid) or preferably in the form of an aqueous solution.
[0058] Organic solvents that can be used to prepare the solution of intermediate N-3 are pure or mixed ethanol, methanol, isopropanol, acetone, methyl butyl ketone (MIBK), ethyl acetate, isopropyl acetate and butyl acetate; the use of isopropyl acetate is preferred. The addition of the acid is carried out at a temperature between 10°C and 35°C, preferably between 20°C and 30°C.
[0059] The isolation of the intermediate N-2 is obtained by filtration after precipitation of the salt from the organic phase acidified by the addition of an antisolvent or by filtration after precipitation of the salt from the corresponding aqueous phase. As antisolvent, C6 and C7 linear, cyclic or branched hydrocarbons can be used pure or mixed together; the preferred compound for this purpose is normal-heptane (n-heptane).
[0060] In an alternative embodiment of the process, the two steps can be carried out as a single step. If the intermediate N-3 is isolated at the end of step c.2) and then redissolved in a solvent for carrying out step d), the two steps are separated; alternatively, if the solvent used in the two steps is the same (e.g. iPrOAc), the acid of step d) can be added directly to the solution of the intermediate N-3 obtained at the end of step c.2), as shown in Example 8, directly from the intermediate N-4 to the intermediate N-2.
[0061] Step e) of the process consists in adding the free radical 2-fluoro-3-methoxyphenyl to the intermediate N-2, through a reaction known as "coupling", to obtain the intermediate N-1:
[0062]
[0063] This reaction can be carried out directly using intermediate N-2.
[0064] The conditions for carrying out this reaction are described in more detail in Example 5, Example 9 and Example 12, and include, for example:
[0065] - reacting in a solvent degassed with nitrogen;
[0066] - adding KOH to a solution of intermediate N-2, followed by heating and subsequent addition of palladium acetate;
[0067] - The reaction is continued at a temperature between 45°C and 55°C for a period between 1 hour and 24 hours, the trend of the reaction being controlled by TLC or HPLC.
[0068] The conditions listed above do not constitute an exhaustive list for performing this step.
[0069] In the event that the reaction is not complete, ethanol may be added to the reaction mixture in order to degrade the unreacted intermediate N-2 (see Example 9 in this regard).
[0070] Finally, the last step f) of the process of the invention consists in hydrolyzing the ester group of the intermediate N-1 with sodium hydroxide and forming the sodium salt of the acid thus obtained, Elagolix sodium salt:
[0071]
[0072] The hydrolysis of esters is a well-known reaction in organic chemistry and the definition of conditions for carrying out it is known to the person skilled in the art.
[0073] The characterizing features of the present invention are in particular that in step b), step c) and step d), they employ intermediate N-5 to intermediate N-2.
[0074] A further object of the present invention is the aforementioned intermediate N-4, intermediate N-3 and intermediate N-2.
[0075] The present invention will be further illustrated by the following examples.
[0076] Experimental apparatus, methods and conditions
[0077] NMR: NMR JEOL 400YH (400 MHz) spectrometer; JEOL Delta v5.1.1 software; spectra recorded in deuterated solvents such as: chloroform-d, D 99.8%, containing 0.1% (v / v) tetramethylsilane (TMS) as internal standard; and chloroform-d, "100%", D 99.96%, containing 0.03% (v / v) TMS, CD3OD and DMSO-d6.
[0078] TLC:MERCK:TLC Silica Gel 60F 254 Aluminium sheet 20x20 cm, cod.1.0554.0001.
[0079] HPLC: Chromatographic system Agilent 1200 Infinity; Detector UV mod. G1315D DAD. Chromatographic conditions:
[0080] - Column: Zorbax eclipse XDB-C18 150x 4.6mm, 3.5μm
[0081] -Flow rate: 1.5ml / min
[0082] -Detector: UV 275nm
[0083] -Injection volume: 5μl
[0084] - Temperature: 20℃
[0085] -Mobile phase A: H2O + 0.05% trifluoroacetic acid (TFA)
[0086] -Mobile phase B: acetonitrile + 0.05% TFA
[0087] Time (min) Mobile phase A (v / v) Mobile phase B (v / v) 0 70 30 0-24 10 90 24-26 2.5 97.5 26-26.2 70 30 26.2-35 70 30
[0088] Chiral HPLC: Chromatographic system Agilent 1200 Infinity; detector UV mod. G1315D DAD. Chromatographic conditions:
[0089] -Column: ASTEC CHIROBIOTIC T (Supelco) 25x4.6 mm, 5μm
[0090] -Flow rate: 1ml / min
[0091] -Detector: UV 275nm
[0092] - Injection volume: 5 μl - Temperature: 25°C
[0093] - Mobile phase A: 95% by volume, methanol brought to pH = 4 with acetic acid
[0094] - Mobile phase B: 5% by volume, buffer solution with ammonium acetate-acetic acid, pH=4.
[0095] LC / Ms / Ms system: Agilent chromatography system model 1100 with UVDAD detector connected to API 2000 mass spectrometer by Applied Biosystem.
[0096] HPTLC:MERCK:HPTLC Silica Gel 60F 254 , where the concentration area is 10x 2.5cm, cod.1.13727.0001.
[0097] TLC detector: Potassium permanganate solution. Preparation: Shake 9 grams of potassium permanganate, 60 grams of potassium carbonate and 900 mL of water until dissolved with 15 mL of 5% sodium hydroxide solution; then soak the plate with the solution and heat until the product is detected.
[0098] DSC analysis was performed using a Perkin Elmer Diamond differential scanning calorimeter. The samples were packaged in aluminum crucibles before analysis. Heating of the samples and reference was performed at a rate of 10°C / min in the temperature range of 25°C-180°C. The thermal maps were analyzed using Pyris Data Analysis 8 Perkin Elmer software.
[0099] DRX diffraction analysis was performed using a Bruker D2 Phaser (version 2) diffractometer operating in Bragg-Brentano geometry and equipped with a rotating 6-position multisampler. The X-ray source used was a tube with a copper anode operated at 30 kV and 10 mA. The analytical wavelength chosen was the Kα of copper obtained by filtering the Kβ using a nickel filter. The X-ray detector used was a solid-state linear detector model LYNXEYE. For analysis, the sample was deposited on a flat single-crystal silicon sample holding plate of the zero background type. The sample was rotated at a speed of 60 rpm during analysis. The analysis was performed in the range of 4°-40° 2θ, with an increase of 0.016° and an acquisition time of 1.0 sec for each increase. The display and processing of the diffraction pattern was performed using Diffrac.EVA (Bruker) software.
[0100] FTIR spectra were acquired using a Thermo Nicolet 6700 spectrophotometer equipped with the ATR accessory Smart iTR model. -1 The sample and background were scanned 64 times at a resolution of 1000 nm to obtain the background immediately before the sample. The FTIR spectra were displayed and processed using Omnic (Thermo Nicolet) software.
[0101] Unless otherwise stated, the water used to conduct the experimental tests was considered pure.
[0102] Unless otherwise stated, organic solvents used in the tests were considered to be “technical” grade.
[0103] Unless otherwise stated, reactants and catalysts used in the tests were deemed to be of commercial grade.
[0104] Example 1
[0105] This example relates to step a) of the process of the present invention, from compound N-6 to intermediate N-5.
[0106]
[0107] 29.95 g of intermediate N-6, 26.86 of D-BOC-phenylglycinol, 30.92 g of triphenylphosphine and 299 mL of tetrahydrofuran were charged into a round bottom flask in this order. It was cooled to 5° C. and a solution of di-tert-butyl azodicarboxylate (27.19 g) dissolved in 150 mL of tetrahydrofuran was added dropwise over about 40 minutes. The system was allowed to reach 25° C. and maintained under stirring for 1.5 hours.
[0108] At the end of the reaction (HPLC control), the solvent was removed by distillation under reduced pressure at 45° C. 377 mL of isopropyl acetate was added to the residue and kept under stirring at 5° C.-10° C. for 1 hour. The suspension was filtered by washing the solid with 20 mL of isopropyl acetate.
[0109] The liquid phase obtained by filtration was concentrated under reduced pressure at 45° C. until a yellow oil was obtained, which was reacted similarly in the subsequent reaction.
[0110] Compound N-6 used as the starting material of the process had the appearance of a white solid; its purity determined by HPLC was 99%.
[0111] 1 H-NMR (400MHz, DMSO-d6): δ11.91 (s, 1H); 7.66 (d, 1H, J = 7.6Hz); 7.59-7.51 (m, 2H); 5.34 (s, 2H); 2.46 (s, 3H);
[0112] pass 1 A sample of intermediate N-5 obtained in the tests of the examples, which was purified specifically for analytical purposes, was analyzed and identified by H-NMR and mass spectroscopy.
[0113] 1 H-NMR (400MHz, DMSO-d6): 7.66 (d, 1H, J = 7.6Hz); 7.61-7.48 (m, 2H); 7.36-7, 21 (m, 5H); 5.3 5(dd,2H,J=22,0 / 17.0Hz); 4.93-4.88(m,1H); 4.10-3.99(m,2H); 2.53(s,3H); 1.35(s,9H).
[0114] Example 2
[0115] This example relates to step b) of the process of the invention.
[0116]
[0117] The intermediate N-5 obtained in the aforementioned embodiment and 120 mL of ethanol were placed in a round-bottom flask. It was kept under stirring at room temperature for 10 minutes. 50 mL of a solution of 34% (by weight concentration) HCl in ethanol was slowly added dropwise and kept under stirring at 25 ° C for 22 hours.
[0118] The reaction was controlled using TLC analysis.
[0119] The solid was filtered by washing with 20 mL of ethanol and dried at 60° C. under reduced pressure for 1 hour. 58.53 g of the product were obtained in the form of a white solid.
[0120] The obtained solid was suspended in 322 mL of methanol and heated to reflux for 30 minutes. It was cooled to 25° C. for 2 hours and then cooled to 0° C. for 1 hour. The solid was filtered by washing with 20 mL of cold methanol and dried under reduced pressure at 60° C. until constant weight.
[0121] 34.4 g of intermediate N-4 were obtained (white solid, purity HPLC 99.7%).
[0122] 1 H-NMR(400MHz,DMSO-d6): δ8.85(br s,2H);7.66(d,1H,J=7.6Hz);7.60-7.53(m,2H);7.39-7.34(m,5H);5.32(d d,2H,J=24.0 / 17.0Hz); 4.49-4.47(m,1H); 4.29-4.26(m,2H); 2.55(s,3H).
[0123] Example 3
[0124] This example relates to the implementation of step c) of the process of the invention.
[0125]
[0126] 5 g of intermediate N-4 was suspended in 23.5 mL of isopropyl acetate in a round bottom flask.
[0127] A solution of potassium carbonate (8.68 g) in water (33.5 mL) was added and kept under vigorous stirring at 25 °C for 2 hours.
[0128] The phases were separated, the organic phase was washed twice with water and 5 mL of N,N-dimethylformamide were added.
[0129] Isopropyl acetate was removed under reduced pressure at 45° C., and 2.0 mL of 4-bromo-butyric acid ethyl ester and 2.9 mL of N,N-diisopropylethylamine were added to the solution. The solution was kept under stirring at 35° C. for 40 hours.
[0130] At the end of the reaction (HPLC analysis was used to control the reaction), it was cooled to 25° C. and 25 mL of water and 25 mL of isopropyl acetate were added.
[0131] The phases were separated, the organic phase was washed with water and concentrated under reduced pressure at 45° C. until constant weight was reached. 5.6 g of a yellow oil were obtained (HPLC purity 94.2%).
[0132] The intermediate N-3 thus obtained was used as it is in the reaction of the following example.
[0133] Example 4
[0134] This example relates to the implementation of step d) of the process of the invention, wherein the protic acid is hydrochloric acid.
[0135]
[0136] The intermediate N-3 obtained as in the previous example was added with 130 mL of isopropyl acetate, to which 1 mL of 37% hydrochloric acid was added, and the temperature was maintained at 25 ° C. The system was kept under stirring and about 90 mL of solvent was distilled under reduced pressure. Another 20 mL of isopropyl acetate was added and concentrated again until a residual volume of about 42 mL. The solution was slowly dripped into 60 mL of n-heptane cooled to 5 ° C. It was kept under stirring at 25 ° C for 3 hours and the solid was filtered by washing with 40 mL of n-heptane. It was dried under reduced pressure and at 45 ° C until constant weight was reached.
[0137] 5.1 g of a white solid were obtained (HPLC purity 91.8%).
[0138] 1 H-NMR (400MHz, DMSO-d6): δ9,75-9-43(m,2H); 7.64(d,1H,J=7.4Hz); 7.58-7.50(m,2H); 7.39-7.31(m,5H); 5.27(t,2H,J=17.8Hz); 4.53-4.50(m, 2H); 4.36-4.29 (m, 1H); 4.01 (dd, 2H, J = 14.2 / 7.3Hz); 2.50 (s, 3H); 2.34- 2.30(m,2H); 1.95-1.80(m,2H); 1.30-1.16(m,2H); 1.12(t,3H,J=7.3Hz).
[0139] Example 5
[0140] This example relates to the implementation of step e) of the process of the invention, wherein intermediate N-2 is salified as the hydrochloride salt.
[0141]
[0142] 5 g of intermediate N-2, 3.27 g of 2-fluoro-3-methoxyphenylboronic acid and 60 mL of acetone previously degassed with nitrogen were loaded into a round-bottom flask. The system was cooled to 15 ° C and a solution of potassium hydroxide (1.62 g) dissolved in water (30 mL) was added. It was brought to 25 ° C and the reaction mixture was degassed for about 10 minutes. 0.45 g of tri-tert-butylphosphonium tetrafluoroborate was added and heated to 45 ° C. After reaching this temperature, 0.17 g of palladium acetate was added and heated to 50 ° C for 1 hour.
[0143] The reaction was controlled using HPLC analysis. At the end of the reaction, it was cooled to 25°C and 25 mL of water and 25 mL of isopropyl acetate were added.
[0144] The phases were separated by filtration over dicalite, the organic phase was washed with water and concentrated under reduced pressure at 45° C. until a residual volume of 24 mL was reached.
[0145] The reaction product dissolved in isopropyl acetate was extracted with a solution of 85% orthophosphoric acid (3.25 g) in water (30 mL).
[0146] The aqueous phase containing the product was first washed with 5 mL of isopropyl acetate and then treated with a solution of potassium carbonate (5.75 g) in water (7.3 mL) and finally extracted with 50 mL of isopropyl acetate. The product went into organic solution.
[0147] The organic phase washed with water was concentrated under reduced pressure at 45°C until it became a yellow oil (crude intermediate N-1).
[0148] The oil dissolved in dichloromethane was filtered over silica gel (25 g) and washed with 730 mL of a 80:20 mixture of methyl chloride / isopropyl acetate.
[0149] The solvent was concentrated under reduced pressure at T = 45°C to obtain 3.9 g of a colorless oil (HPLC purity 98.8%).
[0150] 1 H-NMR (400MHz, DMSO-d6): 7.66 (d, 1H, J = 7, 6Hz); 7.58-7.51 (m, 2H); 7.24-7.16 (m, 7H); 6.73-6.58 (m, 1H); 5.33 (m, 2H); 4.89-4.82 (m, 1H); 4.0 0(dd,2H,J=14.2 / 6.8Hz); 4.03-3.84(m,2H); 3.85(s,3H); 2.34-2.15(m,4H); 2.09(d,3H,J=2.7Hz); 1.53-1.51(m,2H); 1.13(t,3H,J=7.3Hz).
[0151] Example 6
[0152] This example relates to step f) of the process of the invention, obtaining the sodium salt of Elagolix.
[0153]
[0154] 1.84 g of intermediate N-1 and 10 mL of ethanol were charged into a round bottom flask. A solution of sodium hydroxide (0.234 g in 7.36 of water) was slowly dropped and the system was heated to 35°C for 1.5 hours.
[0155] The reaction was controlled using TLC analysis.
[0156] At the end of the reaction, it was cooled to 25°C and the mixture was concentrated under reduced pressure.
[0157] 14mL of water and 14mL of methyl isobutyl ketone are added to the residue, which is heated to 55 ℃ for 10 minutes and separates each phase. The aqueous phase is treated with 4.6mL of 30% sodium hydroxide and extracted twice more with 14mL of methyl isobutyl ketone. The organic phase is washed with 20mL of saturated sodium chloride solution and concentrated under reduced pressure until a yellow oil is obtained. The residue is added with 15mL of methyl isobutyl ketone, and the solution is filtered on a Millipore filter (0.22 μm). It is concentrated under reduced pressure until the residual volume of 6mL is reached, and then slowly dripped into a n-heptane solution (18.4mL) placed under vigorous stirring and at 25 ℃. It is kept under stirring for 1 hour and solid is filtered by washing with n-heptane (4mL).
[0158] This was dried at 45° C. under reduced pressure for 1 hour.
[0159] 1.3 g of Elagolix sodium salt were obtained as a white solid with HPLC purity = 99.0%.
[0160] 0.840 g of crude Elagolix sodium salt was dissolved in 4 volumes of methyl isobutyl ketone (3.36 mL) and slowly dripped into 10 volumes of n-heptane (8.4 mL) placed under vigorous stirring at 25° C. It was kept under stirring for 1 hour, the solid was filtered by washing with n-heptane, and dried at 45° C. under reduced pressure for 30 minutes. The same operation was carried out 3 times to obtain 0.550 g of Elagolix sodium salt as a white solid (HPLC purity = 99.6%; HPLC titer = 99.6%). 1 The H-NMR and MS analytical data were consistent with those reported in the literature. Figure 1 Shown are important parts of the HPLC chromatogram obtained on a product sample in the context of the experimental setup and under the conditions described above.
[0161] The inventors have also noticed that the product contains atropic isomers, i.e. a mixture of conformational isomers, the presence of which is due to the steric hindrance of the substituents present on the central ring in the Elagolix molecule (3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl radical) and on the 2-fluoro-3-methoxyphenyl group attached to the central ring. This steric hindrance prevents free rotation around the bond connecting the two rings, such as Figure 3As shown in the figure: In this figure, the dashed rectangle represents the middle plane of the 3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl ring, and in the first of the two atropisomers (shown at the top of the figure), the 2-fluoro-3-methoxyphenyl group has the fluorine and methoxyphenyl substituents above the plane, while in the second (shown at the bottom of the figure), the substituents are below the plane.
[0162] A sample of the product obtained in this example was then subjected to HPLC analysis on a chiral column in the experimental setup and under the conditions described above. Figure 2 Reappearance in Figure 2 The presence of two peaks due to the two atropisomers separated by the chiral column is reported.
[0163] The ratio between the other atropisomers determined by chiral HPLC was equal to 1.03.
[0164] Comparative Example 7
[0165] This comparative example relates to step c) carried out at a higher temperature (80° C. instead of 35° C.) relative to the conditions of this step according to the invention.
[0166]
[0167] 30 g of intermediate N-4 was suspended in 140 mL of isopropyl acetate in a round bottom flask.
[0168] A solution of potassium carbonate (52 g) in water (200 mL) was added and kept under vigorous stirring at 25 °C for 2 hours.
[0169] The phases were separated, the organic phase was washed twice with water and 30 mL of N,N-dimethylformamide were added.
[0170] Isopropyl acetate was removed under reduced pressure at 45°C, and 10 mL of 4-bromo-butyric acid ethyl ester and 13.60 mL of N,N-diisopropylethylamine were added to the solution.
[0171] The solution was kept under stirring at 80°C for 20 hours.
[0172] At the end of the reaction (HPLC analysis was used to control the reaction), it was cooled to 25° C. and 150 mL of water and 150 mL of isopropyl acetate were added.
[0173] The phases were separated, the organic phase was washed with water and concentrated under reduced pressure at 45° C. until constant weight was reached.
[0174] 33.6 g of a yellow oil were obtained (HPLC purity 59%, major impurity 4%).
[0175] Example 8
[0176] This example relates to steps c) and d) of the process of the invention carried out as a single synthetic step leading to intermediate N-2 salified as the hydrochloride salt from intermediate N-4.
[0177]
[0178] Intermediate N-4 (57.2 g) and isopropyl acetate (268.7 mL) were charged into a round bottom flask under nitrogen. The suspension was kept under stirring (T = 25 ° C for 10 minutes), after which a solution prepared with potassium carbonate (99.4 g) and water (383 mL) was added to the suspension, keeping the temperature below 25 ° C. It was kept under vigorous stirring at 25 ° C for 12 hours.
[0179] The phases were separated, the organic phase was washed with water, and N,N-dimethylformamide (138 mL) was added.
[0180] Residual isopropyl acetate was removed by distillation at 45°C under reduced pressure.
[0181] 4-Bromo-butyric acid ethyl ester (30.5 mL) and N,N-diisopropylethylamine (44.5 mL) were added to the solution, keeping the temperature below 25 °C.
[0182] The solution was heated to 35° C. and kept under stirring at 35° C. for 40 hours (HPLC control at the end of this period).
[0183] It was cooled to 25°C, and 286 mL of water and 286 mL of isopropyl acetate were added.
[0184] The phases were separated and the organic phase was washed with water.
[0185] Isopropyl acetate (550 mL) was added to the organic phase, the solution was cooled to 15°C and 37% hydrochloric acid (10.0 mL) was added, keeping the temperature at about 25°C (pH = 1).
[0186] The solution was concentrated by distillation under reduced pressure, then isopropyl acetate (165 mL) and ethanol (5.8 ml) were added, and it was stirred for several minutes.
[0187] Such a solution was dropped onto n-heptane (705 mL) precooled to 5°C (white solid precipitated).
[0188] The suspension was kept under stirring at 0° C. for 1 hour, then the solid was filtered and dried at 45° C. under reduced pressure until constant weight was reached.
[0189] Intermediate N-2 = 54.5 g (white solid, HPLC purity 92.1%).
[0190] Example 9
[0191] This example relates to step e) of the process of the invention, wherein intermediate N-2 is salified as the hydrochloride salt.
[0192]
[0193] Intermediate N-2 (13.9 g), 2-fluoro-3-methoxyphenylboronic acid (9.56 g) and tri-tert-butylphosphonium tetrafluoroborate (1.24 g) were charged into a round bottom flask under nitrogen.
[0194] Acetone (166.8 mL), previously degassed with nitrogen, was added and kept under stirring at 25 °C by bubbling nitrogen into the solution for 10 minutes.
[0195] The reaction mixture was cooled to 5°C and a solution of potassium hydroxide (5.52 g) in water (55.6 mL) degassed with nitrogen was added, keeping the temperature below 15°C (pH = 9).
[0196] It was heated to 40°C with stirring continued for 1 hour, still bubbling nitrogen into the solution.
[0197] It was heated to 50° C., palladium acetate (0.48 g) was added and it was kept under stirring under nitrogen atmosphere for 16 hours (HPLC control, intermediate N-2 less than 0.2%).
[0198] When HPLC control detected incomplete disappearance of intermediate N-2, ethanol (27.8 mL) was added and stirring was continued for 3 hours (HPLC control, no intermediate N-2 was detected).
[0199] It was cooled to 25°C.
[0200] Water (70 mL) and isopropyl acetate (70 mL) were added.
[0201] The resulting two-phase system is filtered and the phases are separated, and the organic phase is washed with water.
[0202] The organic phase was concentrated under reduced pressure at 40°C until a volume of about 120 mL was reached, which was added to an acidic solution obtained by mixing 85% orthophosphoric acid (10.6 g) with water (100 mL).
[0203] The obtained two-phase system was kept under stirring at 25° C. for 30 minutes.
[0204] The phases were separated: the product was in the aqueous phase which was washed with isopropyl acetate.
[0205] The phases were separated and the aqueous phase (which contained the product) was added dropwise to a basic solution obtained with potassium carbonate (18.83 g) and water (24 mL), keeping the temperature between 25°C and 30°C.
[0206] Isopropyl acetate (163 mL) was added and the two-phase system was stirred at 25 °C for 20 minutes.
[0207] The phases were separated; at this stage in the process the product was contained in the organic phase which was washed with water (74 mL).
[0208] The organic phase was concentrated under reduced pressure at 45° C. until an oil was obtained which was filtered over a layer of silica gel (67.45 g) with a mixture of dichloromethane / isopropyl acetate in the ratio of 80:20.
[0209] The solution was concentrated under reduced pressure at 45°C to obtain 11.0 g of intermediate N-1 (colorless oil, HPLC purity 99%).
[0210] Example 10
[0211] This example relates to the implementation of step c) of the process of the invention.
[0212]
[0213] 5 g of intermediate N-4 was suspended in 23.5 mL of isopropyl acetate in a round bottom flask.
[0214] A solution of potassium carbonate (8.68 g) in water (33.5 mL) was added and kept under vigorous stirring at 25 °C for 2 hours.
[0215] The phases were separated, the organic phase was washed twice with water and 5 mL of N,N-dimethylformamide were added.
[0216] Isopropyl acetate was removed under reduced pressure at 45° C., and 2.0 mL of 4-bromo-butyric acid ethyl ester and 2.9 mL of N,N-diisopropylethylamine were added to the solution. The solution was kept under stirring at 35° C. for 40 hours.
[0217] At the end of the reaction (HPLC analysis was used to control the reaction), it was cooled to 25° C. and 25 mL of water and 25 mL of isopropyl acetate were added.
[0218] The phases were separated and the organic phase was washed successively with water, with aqueous NaCl solution, with acidic 1M aqueous HCl solution, with alkaline 8% aqueous NaHCO3 solution and finally with water.
[0219] The organic phase was concentrated at 45°C under reduced pressure to remove at least 90% of the solvent to afford a yellow oil which was used as such in the reaction in the following example.
[0220] Embodiment 11
[0221] This example relates to the implementation of step d) of the process of the invention, wherein the protic acid is phosphoric acid.
[0222]
[0223] Intermediate N-3 (250 mL) obtained as described in Example 10 was dissolved in 1.1 L of isopropyl acetate.
[0224] The solution was treated with a solution of 85% orthophosphoric acid (57 g) in water (614 mL).
[0225] The phases were separated and the organic phase was re-extracted with a solution of 85% orthophosphoric acid (23.4 g) in water (145 mL).
[0226] The aqueous phase containing the product was kept under stirring at 25° C. until a white solid precipitated, which was filtered off and washed on the filter with water.
[0227] It was dried at 50°C under reduced pressure until a constant weight was reached.
[0228] 231 g of intermediate N-2 were obtained (white solid, HPLC titer 98.1%), which was used directly as such in the next step without any further purification.
[0229] 1 H-NMR (400MHz, CDCl3): 7.67-7.49 (m, 3H); 7.30-7.24 (m, 5H); 5.33 (s, 2H); 4.11-4.05 (m, 3H); 4.00 (dd, 2H, J=7. 5Hz); 2.52-2.50 (m, 3H); 2.37 (t, 2H, J = 6.9Hz); 2.23 (t, 2H, J = 7.3Hz); 1.61-1.57 (m, 2H); 1.13 (t, 3H, J = 7.2Hz).
[0230] Figure 4 , Figure 5 and Figure 6The DRX diffraction spectrum, DSC thermogram and FT-IR spectrum of the intermediate N-2 prepared in this example obtained using the instruments and methods described above are reproduced respectively.
[0231] The composition of the sample was determined using elemental analysis of carbon, hydrogen and nitrogen and using ion chromatography of phosphate, providing the following results: Carbon = 43.62%; Hydrogen = 4.27%; Nitrogen = 5.60%; Phosphate = 15.78% (dihydrogen phosphate of intermediate N-3), according to the proposed structure.
[0232] Example 12
[0233] This example relates to step e) of the process of the invention, wherein intermediate N-2 is salified with phosphoric acid.
[0234]
[0235] In a round-bottom flask under nitrogen, intermediate N-2 (200 g) obtained according to the procedure of Example 11, 2-fluoro-3-methoxyphenylboronic acid (138 g), tri-tert-butylphosphonium tetrafluoroborate (18 g) and acetone (2250 mL) were charged.
[0236] After degassing the suspension with nitrogen, the reaction mixture was cooled to 5°C and a solution of potassium hydroxide (88 g) in water (880 mL) previously degassed with nitrogen was added, keeping the temperature below 15°C.
[0237] It was heated to 45° C., palladium acetate (7 g) was added and it was kept stirring under nitrogen atmosphere for 2 hours (HPLC control, no intermediate N-2 was detected).
[0238] It was cooled to 25°C.
[0239] Water (1000 mL), isopropyl acetate (1000 mL) and decalide were added.
[0240] The system was filtered, the phases were separated and the organic phase was washed with water.
[0241] After the organic phase was concentrated under reduced pressure at 40° C. to a small volume, it was poured into an acidic solution obtained by mixing 85% orthophosphoric acid (117 g) with water (1250 mL).
[0242] The obtained two-phase system was kept under stirring at 25° C. for 30 minutes.
[0243] The phases were separated: the product was in the aqueous phase which was washed with isopropyl acetate.
[0244] The phases were separated and the aqueous phase (which contained the product) was added dropwise to a basic solution obtained with potassium carbonate (271 g) and water (345 mL), keeping the temperature between 25°C and 30°C.
[0245] Isopropyl acetate (2350 mL) was added and the two-phase system was stirred at 25 °C for 20 minutes.
[0246] The phases were separated, the organic phase was washed with water and concentrated under reduced pressure at 45°C until an oil (HPLC purity = 93.6%) was obtained, which was dissolved in dichloromethane (145 ml).
[0247] A portion of the solution (150 mL) was placed under stirring with 70 g of silica gel and 9 g of decolorizing carbon for 2 hours.
[0248] The suspension was filtered by washing the residue with dichloromethane and the organic solution was further filtered on a membrane filter to obtain intermediate N-1 (70 g of oil, HPLC purity = 98.1%) after evaporation of the solvent.
[0249] Such intermediates can be used as such in step f) of the present invention.
[0250] The remainder of the solution containing intermediate N-1 in dichloromethane was filtered on silica gel in the same way as described in Example 5 and used in the subsequent step f) of the present invention.
Claims
1. A process for synthesizing the sodium salt of Elagolix, the process comprising the following steps: a) reacting the compound 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione (N-6) with D-Boc-phenylglycinol to obtain the intermediate 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-pyrimidine-2,4(1H,3H)-dione (N-5): b) treating the intermediate N-5 with hydrochloric acid in a solvent selected from ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone (MIBK), ethyl acetate, isopropyl acetate or a mixture thereof to obtain the intermediate 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[2(R)-amino-2-phenylethyl]-pyrimidine-2,4(1H,3H)-dione hydrochloride (N-4): c) treating the intermediate N-4 with a base and reacting with ethyl 4-bromobutyrate at a temperature between 30°C and 55°C for a period between 18 hours and 48 hours to obtain the intermediate 3-[2(R)-{ethoxycarbonylpropylamino}-2-phenylethyl]-5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione (N-3): d) treating the intermediate N-3 with a protic acid to obtain the corresponding salt: Intermediate N-2: e) reacting the intermediate N-2 with 2-fluoro-3-methoxyphenylboronic acid to obtain the intermediate 3-[2(R)-{ethoxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione (N-1): f) forming the sodium salt of said Elagolix by reacting said intermediate N-1 with sodium hydroxide:
2. The process according to claim 1, wherein the intermediate N-5 obtained in step a) is purified by treating the crude product with an organic ester selected from ethyl acetate (AcOEt), butyl acetate (BuOAc) and isopropyl acetate (iPrOAc) and then removing the by-product of triphenylphosphine used in step a) by filtering at a temperature between 0°C and 25°C.
3. The process according to claim 1 or 2, wherein step b) is carried out by adding hydrochloric acid in the form of a gas or dissolved in an organic solvent, selected from ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone, ethyl acetate, isopropyl acetate and mixtures thereof, to a solution of the intermediate N-5 in an organic solvent at a temperature between 5°C and 35°C.
4. A process according to claim 1 or 2, wherein step c) is carried out in a sequence of two operations, wherein the first c.1 consists in suspending the intermediate N-4 in an organic ester selected from ethyl acetate (AcOEt), butyl acetate (ButOAc) and isopropyl acetate (iPrOAc) and treating the intermediate N-4 with an inorganic base; and the second c.2 consists in reacting the amino function released in operation c.1 with the compound 4-bromo-butyric acid ethyl ester at a temperature between 35° C. and 55° C.
5. A process according to claim 3, wherein step c) is carried out in a sequence of two operations, wherein the first c.1 consists in suspending the intermediate N-4 in an organic ester selected from ethyl acetate (AcOEt), butyl acetate (ButOAc) and isopropyl acetate (iPrOAc) and treating the intermediate N-4 with an inorganic base; and the second c.2 consists in reacting the amino function released in operation c.1 with the compound 4-bromo-butyric acid ethyl ester at a temperature between 35° C. and 55° C.
6. Process according to any one of claims 1, 2 and 5, wherein step d) is carried out in a sequence of two operations, wherein the first d.1 consists in preparing a solution of the intermediate N-3 in an organic solvent selected from ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, butyl acetate and mixtures thereof, and adding to the solution a protic acid as a gas or dissolved in a solvent at a temperature between 10°C and 35°C; and the second d.2 consists in isolating the intermediate N-2, obtained by filtration after precipitation of a salt from an organic phase acidified by the addition of an antisolvent, or by filtration after precipitation of a salt from a corresponding aqueous phase.
7. A process according to claim 3, wherein step d) is carried out in a sequence of two operations, wherein the first d.1 consists in preparing a solution of the intermediate N-3 in an organic solvent selected from ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, butyl acetate and mixtures thereof, and adding to the solution a protic acid as a gas or dissolved in a solvent at a temperature between 10°C and 35°C; and the second d.2 consists in isolating the intermediate N-2, obtained by filtration after precipitation of a salt from an organic phase acidified by the addition of an antisolvent, or by filtration after precipitation of a salt from a corresponding aqueous phase.
8. A process according to claim 4, wherein step d) is carried out in a sequence of two operations, wherein the first d.1 consists in preparing a solution of the intermediate N-3 in an organic solvent selected from ethanol, methanol, isopropanol, acetone, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, butyl acetate and mixtures thereof, and adding to the solution a protic acid as a gas or dissolved in a solvent at a temperature between 10°C and 35°C; and the second d.2 consists in isolating the intermediate N-2, obtained by filtration after precipitation of a salt from an organic phase acidified by the addition of an antisolvent, or by filtration after precipitation of a salt from a corresponding aqueous phase.
9. The process according to any one of claims 1, 2, 5 and 7-8, wherein in step d), hydrochloric acid or phosphoric acid is used as the protic acid.
10. The process according to claim 3, wherein in step d), hydrochloric acid or phosphoric acid is used as the protic acid.
11. The process according to claim 4, wherein in step d), hydrochloric acid or phosphoric acid is used as the protic acid.
12. The process according to claim 6, wherein in step d), hydrochloric acid or phosphoric acid is used as the protic acid.
13. 3-[2(R)-{Ethoxycarbonylpropylamino}-2-phenylethyl]-5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione (Intermediate N-3):
14. Salt of 3-[2(R)-{ethoxycarbonylpropyl-amino}-2-phenylethyl]-5-bromo-1-[2-fluoro-6-(trifluoromethyl)-benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione with protonic acid (Intermediate N-2) 15. The salt according to claim 14, wherein the acid is selected from hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, p-toluenesulfonic acid and trifluoroacetic acid.
16. The salt of claim 15, wherein the acid is selected from hydrochloric acid and phosphoric acid.
17. The salt according to claim 14, wherein the anion A - It is phosphate (PO4 3- ), hydrogen phosphate (HPO4 2- ), dihydrogen phosphate (H2PO4 - ) and mixtures thereof.
